Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval from FDA for Ipratropium Br Nasal Solution
Details : Atrovent-Generic (ipratropium bromide) is an anticholinergic bronchodilator, indicated for treatment of symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Product Name : Atrovent-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Ipratropium Bromide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable